The panel of TR reporter assays utilizes non-human mammalian cells engineered to express human thyroid hormone receptors alpha (NR1A1) and beta (NR1A2), ligand-dependent transcription factors commonly referred to as TRα and TRβ. TheTR reporter cells include the luciferase reporter gene functionally linked to a responsive promoter. Thus, quantifying changes in luciferase expression in the treated reporter cells provides a sensitive surrogate measure of the changes in TRα or TRβ activity. The principal application of this assay panel is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against the human TR"s. TR reporter cells are prepared using the proprietary CryoMite process. This cryo-preservation method yields exceptional cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for cumbersome intermediate treatment steps such as spin-and-rinse of cells, viability determinations, cell titer adjustments, or the pre-incubation of reporter cells prior to assay setup. The nuclear receptor reporter assays are all-inclusive cell-based assay systems. In addition to TR reporter cells, this kit provides two optimized media for use during cell culture and in diluting the user"s test samples, a reference agonist, luciferase detection reagent, and a cell culture-ready assay plate.
TRα Reporter Cells: 1 x 1.0 mL; -80°C▪ TRβ Reporter Cells: 1 x 1.0 mL; -80°C ▪ Cell Recovery Media (CRM): 1 x 10.5 mL; -20°C▪ Compound Screening Media (CSM): 1 x 35 mL; -20°C ▪ L-Triiodothyronine, 30 mM (in DMSO) (reference agonist for TRα and TRβ): 1 x 30 µL; -20°C▪ Detection Substrate: 2 x 3.0 mL; -80°C▪ Detection Buffer: 2 x 3.0 mL; -20°C▪ Plate frame: 1; ambient ▪ snap-in, 8-well strips: 12; ambient